Study of LY573636-Sodium in Patients With Metastatic Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
The primary objective is to estimate the time to progressive disease for patients who receive
LY573636-sodium (hereafter referred to as LY573636) after two previous treatments for
metastatic non-small cell lung cancer. Patients will receive an intravenous infusion of study
drug once every 21 days. Computed tomography (CT)-scans will be done before the first dose
and then after every other treatment.